ClinicalTrials.gg

Program

GAL-101

A development code. Also written as “GAL-101 Salt”, “Uncoated GAL-101 Salt 1170 mg” and “Uncoated GAL-101 Salt 780 mg”.

Its studies are mostly in Geographic Atrophy, led by Galimedix Therapeutics.

Furthest: phase 2, since Oct 23, 20243 company-led studies, 2 open or runningNext primary completion: Mar 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galimedix Therapeutics32 open or runningphase 2since Oct 23, 2024Oct 23, 2024Mar 30, 2028phase 2 · NCT06659549

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2024First study: phase 2 study in Geographic AtrophyFirst studyNCT06659549 · 110 planned · United States, Armenia, France and more
  2. Aug 19, 2026Phase 1 study in Healthy Adult ParticipantsNCT07780604 · 92 enrolled · South Africa
  3. Aug 24, 2026Phase 2 study in Plaque, AmyloidNCT07789873 · 100 planned

Ahead

  1. Mar 30, 2028Primary completion: phase 2 study in Geographic AtrophyNCT06659549
  2. Apr 30, 2028Primary completion: phase 2 study in Plaque, AmyloidNCT07789873

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07789873Plaque, Amyloid2Not yet recruitingApr 30, 2028100
NCT07780604Healthy Adult Participants · South Africa1CompletedSep 18, 202592
NCT06659549Geographic Atrophy · United States, Armenia, France and more2RecruitingMar 30, 2028110

How it is read

Names in the registry

  • “GAL-101”, 1 entry
  • “GAL-101 Salt”, 1 entry
  • “Uncoated GAL-101 Salt 1170 mg”, 1 entry
  • “Uncoated GAL-101 Salt 780 mg”, 1 entry

Codes read as this program: GAL101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
GAL-101 (Galimedix Therapeutics): development program | ClinicalTrials.gg